Method for treating acute vascular optic neuropathy

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with treating acute anterior and posterior ischemic optic neuropathy due to introducing vasodilators and anticoagulants as caffeine, halidor, dicinon in complex therapy in hospital for 10 d. Moreover, it is necessary to perform parabulbar introduction of 0.3 ml dexasone, 0.2 ml caffeine, 0.3 ml emoxipin successively, fractionally every 20 min once daily in combination with daily intramuscular injections once daily of 2.0 ml dicinon and 1.0 ml halidor and intravenous injection of haemodesum by drops per 200.0 ml on the 1st, 3d and 5th d of therapy. Also, it is necessary to carry out 5 seances of hirudotherapy for temple area every other day under coagulogram control. Then one should introduce milgamma, dicinon and nootropil at age-dependent dosages for 1 mo ambulatorily. The innovation provides complex improvement of microcirculation and metabolicocular and cerebral processes, regeneration of nervous tissue and reconstruction of optic nerve's conductivity at decreased frequency of therapeutic side effects.

EFFECT: higher efficiency of therapy.

2 ex, 1 tbl

 

The invention relates to ophthalmology, and can be used in the treatment of acute anterior and posterior ischemic optic neuropathy.

Acute vascular optic neuropathy (ASON) occurs in lesions of blood vessels supplying the optic nerve, and in the pathology of cerebral vessels, characterized by acute blood circulation in the vessels of the optic nerve, leading to damage of the optic nerve fibers and a significant reduction of visual functions. SON leads to a sharp deterioration of blood circulation in the optic nerve and the subsequent death of nerve fibers due to the occurrence of these lesions softening, alopecia of gliosis and proliferation of connective tissue. Acute onset of the disease and poor prognosis require early and adequate treatment. Acute optic neuropathy in cases of inadequate or late timing of treatment invariably leads to a rapid and irreversible decline of visual functions.

There is a method of treatment of acute optic neuropathy by the introduction of anticoagulants and vasodilators (Therapeutic ophthalmology edited by Melkassa. M, Medicine, 1985. str).

However, only the use of vasodilators is not possible to fully improve visual function in severe forms of acute vascular optic neuropathy theloss of vision to light perception, so as, by acting on the whole body, can lead to cardiac arrhythmias, low blood pressure, etc. the Use of heparin is the anticoagulant of direct action, which simultaneously gives vasodilator, anti-inflammatory and hypoinsulinaemia effect, can cause bleeding, and was also used vasodilator, anti-sclerotic agent, vitamins, distracting and resolving therapy.

An object of the invention is the creation of effective treatment of acute vascular optic neuropathy with the aim of improving visual function in these patients due to the comprehensive therapy.

The technical result according to the invention is achieved in that in the method of treatment of acute vascular optic neuropathy, including parabulbar and intramuscular injection of vasodilators and anticoagulants, as these medications use caffeine, galidor, dirinon in treatment in the hospital for 10 days, during this exercise parabulbar introduction 0.3 ml of dexasone, 0.2 ml of caffeine, 0.3 ml of emoxipin consistently, fractionally after 20 min once a day in combination with intramuscular injections of 1 per day 2.0 ml of dicynone, 1.0 ml of galidor and intravenous drip gemodeza 200.0 ml in lane is first, the third and fifth day of treatment, as well as spend 5 sessions of treatment on the area of the temple through the day under the control of the coagulation outpatient continue treatment through the introduction of milgamma, dicynone and nootropil in the age dosage for 1 month (table).

The authors empirically, based on a large clinical experience, picked up the doses and duration of treatment. According to the invention, the introduction of drugs developed taking into account the extent and dynamics of the pathological process in acute vascular optic neuropathy with loss of visual functions to light perception. The advantage of this treatment is well tolerated, easy to perform, rare side effects, the possibility of its termination edema after acute symptomatic and achieve positive dynamics, excluding common complications of the cardiovascular system in this category of patients.

According to the invention, the dose parabulbar (local) injection dexasone, caffeine and emoxipin in the amount of 0.2-0.3 ml within 10 days allow you to create a high concentration of active substance in the vicinity of the retina and optic nerve.

The introduction of complex drugs intramuscularly allows you to Deposit them within 4-6 hours, which potentiates the pharmacodynamics of Lech of the public funds, previously entered parabulbarno. Simultaneous use of parabulbarno, according to the invention, the corticosteroid dexamethasone 0.3 ml promotes fast relief of swelling of glial cell has, the use of antioxidant emoxipin 0.3 ml and caffeine 0.2 ml contributes to the stability and survival of nervous tissue under hypoxic conditions, the recovery of trophic, microcirculation and ultimately restoring the conductivity of the optic nerve. Drug dicine normalizes vascular permeability, improves microcirculation, has a hemostatic effect. Hemostatic effects associated with trigger action on the formation of thromboplastin, however, does not affect prothrombin time, not giperkoagulyatsionnymi properties and does not contribute to the formation of blood clots. Galidor has myotropic antispasmodic and vasodilatory effects, has a weak local anesthetic activity, sedative effect on the Central nervous system. With absolutely no effect on blood pressure.

The mechanism of action due to the ability gemodeza his current start - of low-molecular polyvinylpyrrolidone - link in the body of toxins circulating in the blood, and quickly pull them through the kidney barrier. The drug increases renal blood flow, increases the em glomerular filtration and increases diuresis.

Drug piracetam (nootropil) has a positive effect on metabolism and blood circulation of the brain. Stimulates redox processes, improves regional blood flow in ischemic areas of the optic nerve and brain. Improving energy processes under the influence of piracetam increases the resistance of brain tissue hypoxia and toxic effects. Milgamma - combined preparation containing vitamins C. it stimulates regenerative processes in nervous tissue, antioxidant activity, regulates the nervous system, affecting the transfer of excitation.

The method is illustrated by clinical examples.

Example 1. Patient S., 49 years of age, was diagnosed with acute vascular optic neuropathy. Suffering from diabetes for 10 years. Noted on the morning of the progressive reduction of vision to light perception. Turned in MNTK MG with complaints about the blindness of the left eye.

Admission: visual acuity OD=1.0, the left eye light sensation. The fundus of the eye: optic disc prominenet in the vitreous body, swollen and pale. The boundaries of his stosowana, Vienna full, extended, arteries are narrowed significantly. Confirmed diagnosis: acute vascular optic neuropathy. Were treated in hospital for 10 days by appointment preparato dexason 0.3 ml, caffeine 0.2 ml, emoxipin 0.3 ml, through an irrigation system introduced parabulbarno, consistently, fractionally after 20 min once a day in combination with intramuscular injections of drugs dicine 2.0 ml, galidor 1.0 ml daily 1 time per day and drug gemodez 200.0 ml intravenous drip in the first, third and fifth day of treatment, and conducted 5 sessions of treatment on the area of the temple through the day under the control of coagulation. At the end of inpatient treatment, the visual acuity improved to 0.4, significantly decreased edema and ischemia of the optic nerve. Treatment continued in the outpatient setting by prescription nootropil, milgamma and dicine 1 tablet 2 times a day for 1 month. After treatment, the visual acuity improved to 0.8, completely disappeared edema and ischemia of the optic disk, the disk boundary clearly konturirovany.

Example 2: a Patient, 82 years of age. A history of sudden reduction of vision to sotoodehnia. Visual acuity of the left eye is light perception with the correct projection. The fundus of the eye: optic disc edema, pale, prominenet in the vitreous body, the boundaries are blurred, Vienna expanded arteries are narrowed significantly. Diagnosis: Acute anterior ischemic neuropathy. A comprehensive treatment in hospital for 10 days by prescribing dexason 0.3 ml, FEIN 0.2 ml, the emoxipin 0.3 ml, parabulbarno or through an irrigation system consistently, fractionally after 20 min once a day in combination with intramuscular injections of drugs dicine 2.0 ml, galidor 1.0 ml daily 1 time per day and drug gemodez 200.0 ml intravenous drip in the first, third and fifth day of treatment, and conducted 5 sessions of treatment on the area of the temple through the day under the control of coagulation. Upon completion of the course of inpatient treatment, the visual acuity improved to 0.3, decreased edema and ischemia of the optic nerve. After receiving a positive dynamics in the hospital treatment was continued on an outpatient basis, was appointed: nootropil, milgamma and dicine 1 tablet 3 times a day for 1 month. After treatment, the visual acuity improved to 0.5, the swelling and ischemia of the optic nerve, the boundaries of the optic nerve head clear.

Treatment of OON
Days/remedies1st2nd3rd4th5th6th7th8th9th10thAn outpatient basis up to 1 month
Dexason (p/b)0,30,30,30,30,30,3 0,30,30,30,3
Koffein (p/b)0,20,20,20,20,20,20,20,20,20,2
The emoxipin (p/b)0,30,30,30,30,30,30,30,30,30,32 drops 3 times a day
Dicine (V/m)2,02,02,02,02,02,02,02,02,02,0
Galidor (V/m)1,01,01,01,01,01,01,01,01,01,0
Hirudotherapy+++++
Gemodez (in/in)+++
Nootropil (piracetam) (V/m)5,05,05,05,05,05,05,05,05,05,0
Milgamma (table)+
Dicine (table)+
Nootropil (piracetam) (table)+

The method of treatment of acute vascular optic neuropathy, including parabulbar and nutrim the muscle introduction vasodilators and anticoagulants, characterized in that, as these medications use caffeine, galidor, dirinon in treatment in the hospital for 10 days, during this exercise parabulbar introduction 0.3 ml of dexasone, 0.2 ml of caffeine, 0.3 ml of emoxipin consistently, fractionally after 20 min once a day in combination with daily intramuscular injections of 1 per day 2.0 ml of dicynone and 1.0 ml of galidor and intravenous drip gemodeza 200.0 ml in the first, third and fifth days of treatment, as well as spend 5 sessions of treatment on the area of the temple through the day under the control of the coagulation outpatient continue treatment by introducing milgamma, dicynone and nootropil in the age dosage for 1 month.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves administering pyrimidine nucleotide precursors at a daily dose of 0.05-0.3 g/kg of body weight. The method is applicable under condition that cytotoxic chemotherapy agent does not belong to pyrimidine nucleoside analogs.

EFFECT: enhanced effectiveness in eliminating mitochondrial respiration chain dysfunction.

2 cl

Adaptogen // 2279877

FIELD: organic chemistry, medicine, biochemistry.

SUBSTANCE: invention proposes using acizol representing bis-(1-vinylimidazol-N) zinc diacetate as an adaptogen. Acizol is known early as antidote. Acizol exceeds plant Eleutherecoccus senticosus by activity with respect to indices of functional state of the body adaptation systems due to providing the higher intensity of tissue respiration, improvement of energetic metabolism and regenerative processes.

EFFECT: enhanced effectiveness and valuable medicinal and biochemical properties of adaptogen.

1 dwg, 8 tbl

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should correct hemostasis disorders intra-operationally due to introducing fraxiparine about 40-80 min against the onset of operation along with intravenous injection of mexidol, by drops at the dosage of about 5-6 mg/kg patient's body weight dissolved in 400 ml 0.9%-NaCl solution at the rate of 60 drops/min. The present innovation enables to create the peak of fraxiparine and mexidol concentrations at traumatic stage of operation that enables to correct hemostasiological disorders during operative interference and at early post-operational period due to combined action of preparations onto different links of hemostasis.

EFFECT: higher efficiency and accuracy of correction.

FIELD: organic chemistry, medicine, neurology, pharmacy.

SUBSTANCE: invention relates to derivatives of pyridazinone or triazinone represented by the following formula, their salts or their hydrates: wherein each among A1, A2 and A3 represents independently of one another phenyl group that can be optionally substituted with one or some groups chosen from the group including (1) hydroxy-group, (2) halogen atom, (3) nitrile group, (4) nitro-group, (5) (C1-C6)-alkyl group that can be substituted with at least one hydroxy-group, (6) (C1-C6)-alkoxy-group that can be substituted with at least one group chosen from the group including di-(C1-C6-alkyl)-alkylamino-group, hydroxy-group and pyridyl group, (7) (C1-C6)-alkylthio-group, (8) amino-group, (9) (C1-C6)-alkylsulfonyl group, (10) formyl group, (11) phenyl group, (12) trifluoromethylsulfonyloxy-group; pyridyl group that can be substituted with nitrile group or halogen atom or it can be N-oxidized; pyrimidyl group; pyrazinyl group; thienyl group; thiazolyl group; naphthyl group; benzodioxolyl group; Q represents oxygen atom (O); Z represents carbon atom (C) or nitrogen atom (N); each among X1, X2 and X3 represents independently of one another a simple bond or (C1-C6)-alkylene group optionally substituted with hydroxyl group; R1 represents hydrogen atom or (C1-C6)-alkyl group; R2 represents hydrogen atom; or R1 and R2 can be bound so that the group CR2-ZR1 forms a double carbon-carbon bond represented as C=C (under condition that when Z represents nitrogen atom (N) then R1 represents the unshared electron pair); R3 represents hydrogen atom or can be bound with any atom in A1 or A3 to form 5-6-membered heterocyclic ring comprising oxygen atom that is optionally substituted with hydroxyl group (under condition that (1) when Z represents nitrogen atom (N) then each among X1, X2 and X3 represents a simple bond; and each among A1, A2 and A3 represents phenyl group, (2) when Z represents nitrogen atom (N) then each among X1, X2 and X3 represents a simple bond; A1 represents o,p-dimethylphenyl group; A2 represents o-methylphenyl group, and A3 represents phenyl group, or (3) when Z represents nitrogen atom (N) then each among X1, X2 and X3 represents a simple bond; A1 represents o-methylphenyl group; A2 represents p-methoxyphenyl group, and A3 represents phenyl group, and at least one among R2 and R means the group distinct from hydrogen atom) with exception of some compounds determined in definite cases (1), (3)-(8), (10)-(16) and (19) given in claim 1 of the invention. Compounds of the formula (I) elicit inhibitory activity with respect to AMPA receptors and/or kainate receptors. Also, invention relates to a pharmaceutical composition used in treatment or prophylaxis of disease, such as epilepsy or demyelinization disease, such as cerebrospinal sclerosis wherein AMPA receptors take part, a method for treatment or prophylaxis of abovementioned diseases and using compound of the formula (I) for preparing a medicinal agent used in treatment or prophylaxis of abovementioned diseases.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

32 cl, 10 tbl, 129 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new compounds of the following formulae:

and , and to a pharmaceutical composition possessing the PPAR-ligand binding activity and comprising the indicated compound, and a pharmaceutically acceptable vehicle. Also, invention relates to a method for treatment of patient suffering with physiological disorder that can be modulated with the compound possessing the PPAR-ligand binding activity. Method involves administration to the patient the pharmaceutically effective dose of indicated compound or its pharmaceutically acceptable salt.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

10 cl, 1 tbl, 104 ex

FIELD: topical phyto-mineral compositions for prophylaxis and treatment of infective, respiratory, skin, tumor and other diseases.

SUBSTANCE: claimed composition represents aqueous solution containing as drug plants: everlasting, milfoil, goosegrass, celandine, calendula, bay leave, pine buds, birch buds; as cereals: oat, millet (corn), buckwheat (corn) and wheal (corn); and as mineral components: sea salt and laminaria in amount of 7-9 g per 1000 ml of water, correspondently. In autumn-spring and winter seasons it contains additionally phyto-component such as tutsan, in amount of 7-9 g.

EFFECT: topical composition having no side-effects, with combined component action and increased penetration effect through hypoderm.

2 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out irrigoscopy examination under artificial hypotonia of large intestine with single-stage double opacification of large intestine done with fine peptized aqueous barium cocktail heated to 36°C composed of water - 100 ml, sodium citrate - 1.5 g, sugar - 8 g, barium sulfate - 200 g, carboxymethyl cellulose 0.5 g, raw hen eggs - 2 eggs. Irrigoscopy examination is repeatedly carried out in 24 h. Ribbon-like shadows being observed, intestinal heminthiasis is to be diagnosed.

EFFECT: high reliability in determining shape and localization of helminth even in the cases of negative coprological and serological examination results.

FIELD: medicine.

SUBSTANCE: method involves taking into consideration dose-exposure plot, age, hourly diuresis, hemolysis, exotoxic shock, larynx edema, hemoglobinuria availability, measuring body temperature and evaluating each symptom in points. The points are summed. Their sum being less than -17, favorable prognosis is formulated and line emergency team gives medical care. The sum of points being from -17 to +23, outcome prognosis is doubtful. The sum being greater than +23, the prognosis becomes unfavorable. The last two cases Poison dose is additionally determined irrespectively of exposure, vomiting and its nature, gastroesophageal hemorrhage, hemolysis, oliguria, larynx edema exotoxic shock, hemolysis, hemoglobinuria availability, measuring body temperature and evaluating each symptom in points. The points are summed. Their sum being less than -20, line emergency team gives medical care. The sum of points being greater than +20, resuscitation aid and calling for resuscitation group of emergency team on himself with state stabilization and transporting patient with the resuscitation group to the nearest resuscitation department following. Premedication, analgesics, spasmolytics, corticosteroids and hemostatics are administered with probe-mediated gastric lavage and infusion therapy being started.

EFFECT: enhanced effectiveness of treatment; high objectivity in evaluating patient health state.

1 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with the preparation of antimutagenic activity towards chemical mutagens as betulinic acid previously known as an antimutagen towards ultraviolet and as an antioxidant. The decrease of chromosomal aberrations has been shown in animals towards chemical mutagens of dioxidine and cyclophosphamide due to the action of betulinic acid within wide range of dosages.

EFFECT: higher efficiency.

3 tbl

FIELD: medicine, therapy.

SUBSTANCE: the present innovation deals with preventing post-injection necrosis of soft tissues as a result of false subcutaneous injection of 10%-calcium chloride solution. One should detect the volume of the introduced 10%-calcium chloride solution; then it is necessary to introduce 5-fold volume of 5%-sodium citrate solution against the volume of calcium chloride injected; then one should apply a sac with ice onto the site of injection for the period of 30 min, not less. The innovation suggested enables to inhibit the processes for tissue damage due to binding calcium cations with anions of sodium citrate along transforming soluble calcium salt into insoluble one to stop calcium transport into the cells and, thus, prevents its damaging action.

EFFECT: higher efficiency.

1 ex

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to creating drugs for treatment and prevention of inflammatory lesions of support-motor apparatus (myosites, arthrites, tendovaginites, etc.). Therapeutical composition according to invention contains, wt %: essential oil of silver fir 1.0-2.0, camphor 4.0-5.0, oil extract of red capsicum 0.06-0.08, biologically active component isolated from medicinal leech or its parts 0.01-6.5, Ibuprofen 60.0-65.0, ethoxydiglycol 3.0-5.0, Emulgin B2 0.4-0.6, Carbomer 0.5-0.8, triethanolamine 0.6-0.8, methylparben 0.2-0.3, propylparben 0.02-0.03, butyloxyanisol 0.08-0.1, Bronopol 0.04-0.05, and water the rest. Composition activates metabolic processes in skin and subcutaneous fat layer, normalizes blood supply, eliminates stagnant phenomena, accelerates getting active therapeutical substances into membranes of biological cells, which results in rapid achievement of stable therapeutical effect in what concerns elimination of inflammatory process in joints and muscles.

EFFECT: increased therapeutical efficiency.

2 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: therapeutical composition contains sea-buckthorn extract, biologically active component isolated from medicinal leech or its parts, aqueous-alcoholic extract of horse-chestnut fruitage, methyluracyl, anestesin, Carbomer, triethanolamine, methylparben, Bronopol, butyloxyanisol, and water. Utilization of the composition promotes activation of metabolic processes in rectum mucosa, anesthetizes and accelerates microcirculation of blood, produces antithrombic and thrombolytic effects, which results in rapid achievement of stable therapeutical effect in suppressing hemorrhoids and inflammatory process in rectum.

EFFECT: enhanced therapeutical efficiency.

2 tbl

FIELD: pharmaceutical industry and cosmetics.

SUBSTANCE: composition contains, wt %: biologically active component isolated from medicinal leech or its parts 0.01-6.0, menthol 0.15-0.25, aqueous-alcoholic extract of horse-chestnut fruitage 8-10, camphor 0.15-0.30, ethoxydiglycol 3-5, polyethyleneglycol 1500, 0.8-1.2, emulgin B2, 0.8-1,2, Carbomer 0.6-0.8, triethanolamine 0.6-0.8, methylparben 0.25-0.35, Bronopol 0.04-0.06, butyloxyanisol 0.06-0.08, and water to 100%. Composition is made in the form of gel and provides antithrombic and analeptic effects on skin and hypodermic tissues, enhances antiinflammatory action, favors deep penetration of active components through skin, strengthens venous vessel walls, improves microcirculation of blood, and accelerated restoration of vascular wall tone.

EFFECT: expanded therapeutical possibilities.

2 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: composition has leech-processing product as powder produced from leech after its being subjected to sublimation drying without extracting and crushing into powder and pharmaceutically or cosmetically acceptable carrier. Fine powder produced from whole leeches is used as processing product. Its concentration in mentioned carrier is equal to 0.000001%-11%.

EFFECT: enhanced effectiveness of skin treatment.

FIELD: medicine, biology, in particular pharmakinetics.

SUBSTANCE: leeches are held in active hunger regime to fully blood remove from enteric canal. Then leeches are washer, coarsely minced, lyophilized and ground to produce ultrafine powder (approximately 10-9 m), followed by drug producing therefrom. Preparation is produced at temperature lower than decomposition temperature of bioactive substances containing in preparation, preferably not higher than 4°C. Claimed preparation has biological activities by 50-60 % higher than acceptable ones.

EFFECT: bioactive preparation of improved activity.

2 cl, 1 ex, 1 tbl

FIELD: medicine preparations based on bioactive substances producing by blood-sucker.

SUBSTANCE: claimed method includes application polyvinyl alcohol and magnesium chloride polyhydrate complex as extractant for bioactive substances producing by blood-sucker. Blood-sucker living persons are extracted without lyophilization or grinding.

EFFECT: new pharmaceutical with antiinflammation, anticoagulant and analgesic action.

5 ex, 2 tbl, 2 cl

Massage cream // 2261085

FIELD: cosmetology.

SUBSTANCE: invention relates to manufacturing creams used for massage. The massage cream comprises extracts of medicinal plants, menthol, perfume oil, cosmetic oil, emulsifying agent, preserving agent and water and, additionally, it comprises also a biologically active component isolated from a medicinal leech or its parts, fir essential oil, camphor, stearyl/cetyl alcohol, silicon and these components are taken in the definite quantitative ratio. Cream provides deep penetration of active components through skin, enhances blood microcirculation, shows the immunostimulating and antithrombosis effect on skin and subcutaneous tissues and doesn't cause discomfort and allergy also.

EFFECT: improved and valuable cosmetic and medicinal properties of cream.

1 tbl

FIELD: cosmetic industry, cosmetology.

SUBSTANCE: invention relates to cosmetic agents used for removing bruises and hematomas with masking effect. The curative-cosmetic tone agent comprises a biologically active component isolated from medicinal leech or its parts, pentoxifylline, titanium dioxide, ethoxydiglycol, iron oxide pigments, carbomer, triethanolamine, methylparaben, bronopol, butyloxyanisole, aromatic principle and water wherein components are taken in the definite quantitative ratio. The tone agent provides deep penetration of active component into kin, activates microcirculation and metabolic processes in skin and muscles and reduces skin intumescence.

EFFECT: valuable cosmetic and medicinal properties of agent.

1 tbl, 12 ex

FIELD: medicine, diagnostics.

SUBSTANCE: it is necessary to detect pulsing points beyond umbilical ring to perform manual impact upon them, additionally, one should apply medicinal leeches onto areas of umbilical ring, pulsing points, anus and for projection of a sick organ. Moreover, the areas mentioned should be affected once, not less during a course that enhances blood and lymph outflow in disease focus.

EFFECT: higher efficiency of therapy.

1 ex

The invention relates to medicine, dentistry

FIELD: production of biologically active compounds useful in producing of biologically active food supplements, functional foodstuffs, feed additives for prophylaxis of selenium failure in human and animals.

SUBSTANCE: bioactive substance selenopyran has antioxidant, antiatherogenic, detoxifying, hypolipidemic, immunomodulating and other properties, as well as anabolic effect. Method for production thereof includes providing of 9-phenyl-symmetric octahydroxanthene slurry in ice acetic acid. Then slurry is saturated in inert atmosphere with hydrogen chloride for 15 min and further with mixture of hydrogen selenide and hydrogen chloride for 15 min. Then hydrogen selenide is passed for 2 hours. Preferable temperature of aqueous solution is 20-50°C, and total hydrogen selenide consumption is 2.3-2.3 l. After dissolving of 9-phenyl-symmetric octahydroxanthene acetic anhydride is introduced into reaction mixture and saturation with hydrogen selenide is carried out. Precipitated crystal deposit is filtered and recrystallized from acetone with filtration of hot solution through filter to produce selenopyran with yield up to 92-96 %; purity of at least 92.2 % and selenium content in target product of 23.2-24.0 %.

EFFECT: effective and accelerated method for bioactive selenopyran production with increased yield.

13 cl, 5 tbl, 11 ex

Up!